Loading
CI
Chimerix Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Nov 2023.
Chimerix Inc: what insiders have been doing
Chimerix Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Chimerix Inc in twelve months, the latest record being from 21 April 2025.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
67
Thresholds
n/a
Buy Volume
€308,151
14 ops. · all time
Sell Volume
€44M
28 ops. · all time
Who traded when
BuySaleDavid Jakeman2 sales
Michael T. Andriole2 sales
Michelle LaSpaluto2 sales
Allen S. Melemed1 sale
Michael Albert Alrutz1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$182.5k
Gross profitUS$182.5k100% margin
Net income-US$76.1M-41692.0% margin
Last declaration on 21 April 2025
Declarations67 total
60,828 shares@ US$8.55100.0% of flowCommon StockSEC:0001415889-25-011079:0
630,828 shares@ US$8.5594.8% of flowCommon StockSEC:0001415889-25-011066:0
173,852 shares@ US$8.5599.0% of flowCommon StockSEC:0001415889-25-011074:0
216,689 shares@ US$8.5599.6% of flowCommon StockSEC:0001415889-25-011064:0
87,000 shares@ US$8.5560.5% of flowCommon StockSEC:0001415889-25-011081:0
72,055 shares@ US$8.5594.1% of flowCommon StockSEC:0001415889-25-011069:0
181,541 shares@ US$8.5598.8% of flowCommon StockSEC:0001415889-25-011073:0
35,150 shares@ US$8.5590.2% of flowCommon StockSEC:0001415889-25-011075:0
156,209 shares@ US$8.5591.1% of flowCommon StockSEC:0001415889-25-011070:0
40,000 shares@ US$8.5563.0% of flowCommon StockSEC:0001415889-25-011076:0
2,260 shares@ US$4.51130.7% of flowCommon StockSEC:0001415889-25-004212:0
300 shares@ US$4.5320.1% of flowCommon StockSEC:0001415889-25-004213:0
7,370 shares@ US$4.51590.6% of flowCommon StockSEC:0001415889-25-004218:0
3,065 shares@ US$4.5021.0% of flowCommon StockSEC:0001415889-25-004219:0
1,600 shares@ US$4.51650.4% of flowCommon StockSEC:0001415889-25-004216:0
2,800 shares@ US$4.09650.9% of flowCommon StockSEC:0001415889-25-002500:0
2,350 shares@ US$4.10050.2% of flowCommon StockSEC:0001415889-25-002496:0
1,015 shares@ US$4.110.3% of flowCommon StockSEC:0001415889-25-002498:0
41,667 shares0Common StockSEC:0001415889-25-001220:0
10,855 shares0Common StockSEC:0001415889-25-001222:0
54,275 shares0Common StockSEC:0001415889-25-001221:0
41,667 shares0Common StockSEC:0001415889-25-001224:0
150,000 shares0Common StockSEC:0001415889-25-001219:0
45,925 shares0Common StockSEC:0001415889-25-001223:0
60,000 shares0Common StockSEC:0001415889-24-025802:0
25 of 67 declarations
About Chimerix Inc
Chimerix Inc. (NASDAQ: CMRX) is a United States-based biopharmaceutical company listed on the NASDAQ market in the United States, headquartered in Durham, North Carolina. For investors, the company represents a specialty healthcare name focused on developing novel therapies for severe diseases, with its current strategic identity centered on oncology and rare-disease drug development. Chimerix was founded in 2000 and originally built its platform around antiviral technologies before gradually shifting its portfolio toward higher-value clinical programs, especially in oncology. ([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-acquires-oncoceutics-expand-pipeline-late-stage?utm_source=openai))
Today, Chimerix’s core value driver is its lead asset, dordaviprone, also known as ONC201. The company describes it as a first-in-class small-molecule imipridone being developed for H3 K27M-mutant diffuse glioma, a rare and highly aggressive brain tumor with substantial unmet medical need. In February 2025, Chimerix announced that the FDA had accepted its New Drug Application and granted Priority Review, with a PDUFA target action date of August 18, 2025. That regulatory milestone is central to the investment case and could be transformative if it results in approval. ([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-fda-acceptance-and-priority-review-new-drug?utm_source=openai))
Read moreShow less
From a competitive standpoint, Chimerix is a highly focused biotech rather than a diversified pharmaceutical group. Its narrow pipeline increases concentration risk, but it also gives the company meaningful operating leverage if dordaviprone succeeds commercially. Management has highlighted the drug’s potential to become the first approved therapy specifically for recurrent H3 K27M-mutant diffuse glioma, which would create an important first-mover position in a small but medically urgent market. ([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-fda-acceptance-and-priority-review-new-drug?utm_source=openai))
Historically, Chimerix began as an antiviral company, building around oral antiviral candidates such as brincidofovir. Over time, the company reallocated capital toward oncology, notably through the 2021 acquisition of Oncoceutics, which brought ONC201 into the portfolio. It also monetized TEMBEXA in 2022, underscoring a strategic pivot toward its lead clinical oncology asset. This sequence suggests a company that has deliberately narrowed its scope to maximize the probability of creating value around its most promising program. ([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-acquires-oncoceutics-expand-pipeline-late-stage?utm_source=openai))
Geographically, Chimerix operates primarily from the United States and collaborates with clinical sites in the U.S. and abroad for its development programs. Recent 2025 company communications have emphasized regulatory progress and preparation for a potential commercial launch. For market participants, Chimerix should be viewed as a catalyst-driven biotech where valuation is likely to be highly sensitive to FDA outcomes, clinical data, and commercialization execution in H3 K27M-mutant diffuse glioma. ([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-fda-acceptance-and-priority-review-new-drug?utm_source=openai))
